Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DMF5 Allogeneic Cell Therapy for Metastatic Melanoma
NCT00924001Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Aug 2007
- Primary completion
- Oct 2010
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of anti-MART-1 F5 T-cell receptor in melanoma, sponsored by National Cancer Institute. Started Aug 2007; status: terminated.
02
Drugs
anti-MART-1 F5 T-cell receptor
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00924001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00924001.